Department of Radiology, University of Bonn, Sigmund-Freud-Str. 25, 53129, Bonn, Germany,
Cardiovasc Intervent Radiol. 2014 Oct;37(5):1352-7. doi: 10.1007/s00270-014-0853-x. Epub 2014 Feb 14.
To describe the feasibility of vascular access closure in arteries other than the common femoral artery (CFA) using the ExoSeal vascular closure device (VCD).
Between December 2011 and August 2013, 8 patients (4 males, 4 females, mean age 64 years [range 42-81]) underwent 13 extrafemoral access site closure using the ExoSeal VCD (brachial artery n = 7, venous femoropopliteal bypass n = 3, femoropopliteal segment n = 2, proximal superficial femoral artery n = 1). Patient history, procedural characteristics, and complications were recorded.
Technical success was achieved in 12 of 13 VCD procedures. In 1 case of brachial puncture, safe plug-deployment was not possible, so manual compression was applied. In this case, angiographic and clinical control showed residual bleeding 5 min after the procedure. After additional manual compression for 5 min, the haemorrhage stopped, but a hematoma <3 cm was detectable (procedural success rate 12 of 13 closures). Overall no major complications were observed. Heparin, 5,000 IU, was administered in all cases. Six ExoSeal closures were performed under additional acetylsalicylic acid (ASS) and clopidogrel, three under additional ASS, and the remaining four under heparin only. International normalized ratio and thrombocytes were within normal values in all patients.
Successful vascular access closure using the ExoSeal VCD in puncture sites other than the CFA is feasible with a low complication rate. These applications, however, remain an "off-label" use in selected patients.
描述使用 ExoSeal 血管闭合装置(VCD)在股动脉(CFA)以外的动脉进行血管通路闭合的可行性。
2011 年 12 月至 2013 年 8 月,8 例患者(4 名男性,4 名女性,平均年龄 64 岁[范围 42-81])接受了 13 例股外动脉入路的闭合术,其中 7 例采用 ExoSeal VCD 闭合肱动脉,3 例采用静脉股腘旁路,2 例采用股腘段,1 例采用股浅动脉近端。记录患者病史、手术特点和并发症。
13 例 VCD 手术中有 12 例达到技术成功。在 1 例肱动脉穿刺中,安全的塞子部署是不可能的,因此采用了手动压迫。在这种情况下,血管造影和临床检查显示术后 5 分钟仍有出血。在额外的手动按压 5 分钟后,出血停止,但仍可检测到 <3 cm 的血肿(13 例闭合中有 12 例手术成功率)。总体上未观察到重大并发症。所有病例均给予肝素 5000 IU。6 例 ExoSeal 闭合在加用乙酰水杨酸(ASS)和氯吡格雷,3 例加用 ASS,其余 4 例只用肝素。所有患者的国际标准化比值和血小板均在正常范围内。
使用 ExoSeal VCD 在 CFA 以外的穿刺部位成功进行血管通路闭合是可行的,并发症发生率低。然而,这些应用在选定的患者中仍然是“超适应证”使用。